Zomiradomide

Overview

Zomiradomide (KT-413) is an orally active IRAK4 PROTAC degrader with a DC 50 of 6 nM. Zomiradomide inhibits the NF-κB signaling pathway, while its molecular glue function mediates the degradation of Ikaros and Aiolos (with a DC 50 of 1 nM for both), activates the IFN-I signaling pathway, and selectively degrades IMiD substrates. Zomiradomide inhibits cancer cell proliferation and tumor growth. Zomiradomide can be used in research related to B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. (Pink: IRAK4 ligand ( HY-168311 ); Blue: Cereblon ligand ( HY-W039116 ); Black: linker ( HY-168313 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Hodgkin Lymphoma | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Zinc Finger Protein | Products > Signaling Pathways > Molecular Glues | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > IRAK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > IFNAR

Product Information

• Catalog No.: HY-153368
• CAS No.: 2655656-99-6
• Molecular Formula: C45H48F3N7O6S
• Molecular Weight: 871.97
• Purity: 98.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source